N,N-dimethyl-2-[4-[[3-methyl-5-phenylmethoxy-2-(4-phenylmethoxyphenyl)indol-1-yl]methyl]phenoxy]ethanamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N,N-dimethyl-2-[4-[[3-methyl-5-phenylmethoxy-2-(4-phenylmethoxyphenyl)indol-1-yl]methyl]phenoxy]ethanamine
• 化学式: C₄₀H₄₀N₂O₃
• 分子量: 596.8
• InChiKey: KZFTVQZQKOJOCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.6
• 重原子数：
  45
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  35.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Combinations of SSRI and estrogenic agents
  申请人：Wyeth

  公开号：EP1990051A1

  公开（公告）日：2008-11-12

  This invention comprises methods of treating depression, anxiety, generalized anxiety disorder (GAD), hot flush, post partum depression, premenstrual syndrome, obesity, obsessive compulsive disorder, post-traumatic stress disorder, social phobia, disruptive behavior disorders, impulse control disorders, borderline personality disorder, chronic fatigue disorder, premature ejaculation, pain, attention deficit disorders, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa, or Shy Drager Syndrome comprising administration of a selective serotonin reuptake inhibitor and compound of the formula I or II: wherein Z is a moiety selected from the group of: wherein: R1 is selected frm H, OH or the C1-C12 esters or C1-C12 alkyl ehers thereof, benzyloxy, or halogen; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 are H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H, R2 is not OH; Y is as defined; or a pharmaceutically acceptable salt thereof.

  本发明包括治疗抑郁症、焦虑症、广泛性焦虑症（GAD）、热潮红、产后抑郁症、经前期综合征、肥胖症、强迫症、创伤后应激障碍、社交恐惧症、破坏性行为障碍、冲动控制障碍的方法、或多动症、吉尔-德拉图雷特综合征、神经性贪食症或羞怯-德雷格综合征，包括给药选择性血清素再摄取抑制剂和式 I 或式 II 的化合物：其中 Z 是选自以下组别的分子： 其中R1 选自 H、OH 或其 C1-C12 酯或 C1-C12 烷基醚、苄氧基或卤素；或 C1-C4 卤化醚，包括三氟甲基醚和三氯甲基醚；R2、R3、R4、R5 和 R6 是 H、OH 或 C1-C12 酯或其 C1-C12 烷基醚、卤素或 C1-C4 卤化醚、氰基、C1-C6 烷基或三氟甲基，但当 R1 是 H 时，R2 不是 OH；Y 如所定义；或其药学上可接受的盐。
• Estrogenic agents
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0802183B1

  公开（公告）日：2001-10-10
• [EN] THERAPY FOR INHIBITING SPHINCTER INCONTINENCE<br/>[FR] THERAPIE PERMETTANT D'INHIBER L'INCONTINENCE DU SPHINCTER
  申请人：AMERICAN HOME PROD

  公开号：WO2002003989A2

  公开（公告）日：2002-01-17

  This invention comprises methods of inducing or maintaining sphincter continence, or inhibiting or alleviating incontinence, in a mammal comprising administration of a compound of the formulae I or II: wherein Z is a moiety selected from the group of formulae III or IV wherein: R1 is selected from H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, benzyloxy, or halogens; or C1-C4 halogenated; R2, R3, R4, R5, and R6 are H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, CN, C1-C6 alkyl, or CF3, with the proviso that, when R1 is H, R2 is not OH; Y is the moiety formulae V: R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof and optionally an estrogen.